{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T14:27:41Z","timestamp":1782743261534,"version":"3.54.5"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Journal of Medical Microbiology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ijmmb.2024.100602","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T17:45:51Z","timestamp":1715103951000},"page":"100602","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Possible impact of revisions in disc diffusion breakpoints for aminoglycosides and piperacillin\/tazobactam in the 33rd edition of CLSI M100 document on clinical reporting and use in Indian settings with low susceptibility"],"prefix":"10.1016","volume":"49","author":[{"given":"Prabhav","family":"Aggarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonal","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazia","family":"Nagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijmmb.2024.100602_bib1","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2023"},{"issue":"12","key":"10.1016\/j.ijmmb.2024.100602_bib2","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1517\/14656566.2013.806486","article-title":"Aminoglycoside therapy in infectious diseases","volume":"14","author":"Poulikakos","year":"2013","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.ijmmb.2024.100602_bib3","unstructured":"Clinical and Laboratory Standards Institute (CLSI). AST news update June 2023: New! CLSI M100-ED33: Updated aminoglycoside breakpoints for Enterobacterales and pseudomonas aeruginosa. Available at: \u2264https:\/\/clsi.org\/about\/blog\/ast-news-update-june-2023-new-clsi-m100-ed33-updated-aminoglycoside-breakpoints-for-enterobacterales-and-pseudomonas-aeruginosa.> Accessed September 30, 2023."},{"issue":"suppl_1","key":"10.1016\/j.ijmmb.2024.100602_bib4","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy209.170","article-title":"2562. re-appraisal of aminoglycoside (AG) susceptibility testing breakpoints based on the application of pharmacokinetics\u2013pharmacodynamics (PK-PD) and Contemporary Microbiology Surveillance Data","volume":"5","author":"Bhavnani","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijmmb.2024.100602_bib5","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2022"},{"key":"10.1016\/j.ijmmb.2024.100602_bib6","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2021"},{"key":"10.1016\/j.ijmmb.2024.100602_bib7","series-title":"Guidelines for ATC classification and DDD assignment","year":"2023"},{"issue":"Suppl 2","key":"10.1016\/j.ijmmb.2024.100602_bib8","first-page":"35","article-title":"The pharmacodynamic bases of the prescription of antimicrobials","volume":"32","author":"Perea","year":"2019","journal-title":"Rev Espa\u00f1ola Quimioter"},{"key":"10.1016\/j.ijmmb.2024.100602_bib10","first-page":"67","article-title":"Recommendations of gentamicin dose based on different pharmacokinetic\/pharmacodynamic targets for intensive care adult patients: a redefining approach","volume":"15","author":"Abbasi","year":"2023","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.ijmmb.2024.100602_bib11","volume":"10","author":"Sader","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijmmb.2024.100602_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/2049936120952604","article-title":"Plazomicin: a new aminoglycoside in the fight against antimicrobial resistance","volume":"7","author":"Clark","year":"2020","journal-title":"Therapeutic Advances in Infectious Disease"},{"issue":"2","key":"10.1016\/j.ijmmb.2024.100602_bib13","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.01617-22","article-title":"Evaluation of piperacillin-tazobactam testing against enterobacterales by the Phoenix, MicroScan, and VITEK2 tests using updated clinical and Laboratory Standards Institute breakpoints","volume":"61","author":"Manuel","year":"2023","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijmmb.2024.100602_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijmmb.2023.100432","article-title":"Introducing the new face of CLSI M100 in 2023: an explanatory review","volume":"46","author":"Rai","year":"2023","journal-title":"Indian J Med Microbiol"},{"issue":"10","key":"10.1016\/j.ijmmb.2024.100602_bib15","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E. coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ijmmb.2024.100602_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-040210","article-title":"Piperacillin-tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen)","volume":"11","author":"Bitterman","year":"2021","journal-title":"BMJ Open"}],"container-title":["Indian Journal of Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S025508572400077X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S025508572400077X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T04:26:13Z","timestamp":1718425573000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S025508572400077X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":15,"alternative-id":["S025508572400077X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijmmb.2024.100602","relation":{},"ISSN":["0255-0857"],"issn-type":[{"value":"0255-0857","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Possible impact of revisions in disc diffusion breakpoints for aminoglycosides and piperacillin\/tazobactam in the 33rd edition of CLSI M100 document on clinical reporting and use in Indian settings with low susceptibility","name":"articletitle","label":"Article Title"},{"value":"Indian Journal of Medical Microbiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijmmb.2024.100602","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Indian Association of Medical Microbiologists. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100602"}}